NCT05154994View on ClinicalTrials.gov

Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

April 1, 2026

Study Completion Date

November 30, 2027

Conditions
Infiltrating Urothelial Carcinoma, Sarcomatoid VariantLocally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
Interventions
DRUG

Belinostat

Given IV

BIOLOGICAL

Durvalumab

Given IV

Trial Locations (1)

84112

RECRUITING

Huntsman Cancer Institute/University of Utah, Salt Lake City

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Utah

OTHER